Silke Duerr‐Stoerzer

Determination of HER2 status using both serum HER2 levels and circulating tumor cells in patients with recurrent breast cancer whose primary tumor was HER2 negative or of unknown HER2 status

Tanja Fehm, Sven Becker, Silke Duerr‐Stoerzer et al. · Breast Cancer Research · 2007 · 194 citations · Full text

Inhibition of effector B cells by ibrutinib in systemic sclerosis

Jakob Einhaus, Ann‐Christin Pecher, Elisa Asteriti et al. · Arthritis Research & Therapy · 2020 · 42 citations · Full text

Inhibition of DOT1L and PRMT5 promote synergistic anti-tumor activity in a human MLL leukemia model induced by CRISPR/Cas9

Kathy-Ann Secker, Hildegard Keppeler, Silke Duerr‐Stoerzer et al. · Oncogene · 2019 · 37 citations

Off-target Effect, Synergistic Anti-tumor Activity, Gene Editing +7

MAT2A as Key Regulator and Therapeutic Target in MLLr Leukemogenesis

Kathy-Ann Secker, Bianca Bloechl, Hildegard Keppeler et al. · Cancers · 2020 · 31 citations · Full text

Culture-Expanded Human Invariant Natural Killer T Cells Suppress T-Cell Alloreactivity and Eradicate Leukemia

Hannes Schmid, Corina Schneidawind, Simona Jahnke et al. · Frontiers in Immunology · 2018 · 23 citations · Full text